Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
VITAE SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of Vitae Pharmaceuticals, Inc. (VTAE) Over the Proposed Sale of the Company to Allergan plc Faruqi & Faruqi...
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by...
The following statement is being issued by Levi & Korsinsky, LLP: To: All Persons or Entities who purchased Vitae Pharmaceuticals, Inc. (“Vitae Pharmaceuticals”) (NASDAQ: VTAE) stock...
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by...
Harwood Feffer LLP Announces Investigation of Vitae Pharmaceuticals, Inc. PR Newswire NEW YORK, Sept. 14, 2016 NEW YORK, Sept. 14, 2016 /PRNewswire/ -- Harwood Feffer LLP (www.hfesq.com) is...
Rigrodsky & Long, P.A.: Do you own shares of Vitae Pharmaceuticals, Inc. (NASDAQ GM: VTAE)? Did you purchase any of your shares prior to September 14, 2016? Do you think the...
Allergan to Acquire Vitae Pharmaceuticals Adding Innovative Development Programs for Dermatologic Conditions - Acquisition Adds Differentiated Development Programs to Strengthen Allergan's...
FORT WASHINGTON, Pa., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Jeffrey Hatfield, President...
FORT WASHINGTON, Pa., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Jeffrey Hatfield, President and...
FORT WASHINGTON, Pa., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced the appointment of Scott Applebaum...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 26 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 52 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 156 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| 260 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
